First Manhattan CO Akari Therapeutics PLC Transaction History

First Manhattan CO

  • $29.7 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

Apr 20, 2018
SELL
$1.77 - $4.39 $708 - $1,755
-400 Closed
0 $0
Q4 2017

Jan 22, 2018
BUY
$4.08 - $7.4 $1,632 - $2,960
400
400 $1,000

About Akari Therapeutics Plc

AKTX Quotes by TradingView
  • Ticker AKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,349,200
  • Market Cap $165M
  • Description
  • Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...
More about AKTX
Track This Portfolio

Track First Manhattan CO Portfolio

Follow First Manhattan CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email